Articles tagged with Cell Metabolites
Researchers have developed a nondestructive imaging technique to measure single-cell immune metabolism in real patient blood samples, providing a higher level of information than current clinical techniques. This breakthrough could improve disease diagnosis and treatment for conditions like blood cancers, lupus, and sepsis.
Researchers at Brown and U.T. Southwestern have identified a key mechanism underlying GPT2 deficiency, a rare genetic disease affecting brain development. Supplementing a metabolite called alpha-ketoglutarate may improve DNA structure and gene expression in the brain, potentially leading to new treatments.
Researchers discovered that erucamide inhibits Type III Secretion injectisome assembly in Gram-negative bacteria, enhancing plant immunity and reducing disease susceptibility. Exogenous application of erucamide protects crops from bacterial diseases, offering a potential biopesticide for sustainable agriculture.
Researchers at U of T have developed a new platform called smol-seq that uses DNA sequencing to detect metabolites. This method enables the analysis of hundreds of metabolites simultaneously, making it faster and more precise than current methods.
Researchers at Gladstone Institutes have made a groundbreaking discovery about how neurons consume and metabolize glucose, a process crucial for maintaining normal energy levels. The study found that neurons rely on glycolysis to break down glucose, and its disruption can lead to severe learning and memory problems in mice.
Researchers at Hokkaido University discovered itaconate's modulatory effect on T helper and T regulatory cells, potentially leading to new treatments for autoimmune diseases. The study found that itaconate inhibits Th17 cell differentiation and promotes Treg cell development, reducing disease symptoms in mice models.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
A study found novel biomarkers associated with incident heart failure, including adiponectin and pyruvate, which were linked to increased risk after 8.8 years of follow-up. Chronic inflammation and metabolic changes were also identified as key factors.